Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of Company Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $32.67, for a total transaction of $107,418.96. Following the completion of the transaction, the insider directly owned 35,565 shares of the company’s stock, valued at approximately $1,161,908.55. This trade represents a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

CSTL traded up $0.51 during trading hours on Thursday, hitting $34.50. The company’s stock had a trading volume of 440,800 shares, compared to its average volume of 398,699. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -44.81 and a beta of 1.00. The business’s 50-day moving average price is $34.30 and its 200-day moving average price is $28.42. The company has a current ratio of 5.28, a quick ratio of 5.12 and a debt-to-equity ratio of 0.01. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.22. Castle Biosciences had a negative net margin of 6.10% and a negative return on equity of 4.89%. The business had revenue of $101.95 million during the quarter, compared to analyst estimates of $92.76 million. Sell-side analysts expect that Castle Biosciences, Inc. will post -0.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CSTL. Allworth Financial LP raised its stake in shares of Castle Biosciences by 255.3% in the third quarter. Allworth Financial LP now owns 938 shares of the company’s stock valued at $33,000 after acquiring an additional 674 shares during the period. NFSG Corp purchased a new position in shares of Castle Biosciences during the 3rd quarter worth about $36,000. Global Retirement Partners LLC bought a new position in Castle Biosciences during the 2nd quarter valued at about $26,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Castle Biosciences during the 3rd quarter valued at about $55,000. Finally, Quantbot Technologies LP bought a new position in Castle Biosciences during the 2nd quarter valued at about $62,000. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of Castle Biosciences from a “hold” rating to a “buy” rating in a report on Sunday, November 1st. Mizuho began coverage on Castle Biosciences in a research note on Thursday, October 29th. They set an “outperform” rating and a $60.00 price objective on the stock. BTIG Research upped their price objective on Castle Biosciences from $44.00 to $52.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday, October 29th. Finally, Robert W. Baird raised their price objective on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.50.

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.